ArticleDrugs in R&D2023

Simvastatin Preferentially Targets FLT3/ITD Acute Myeloid Leukemia by Inhibiting MEK/ERK and p38-MAPK Signaling Pathways.

Genhong Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.